Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of ...

A large analysis of two major clinical trials has found that the spread of prostate cancer can be detected on imaging scans even when biomarkers remain stable in patients treated with androgen ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

Know the 8 prostate cancer symptoms to watch for, from urinary changes to bone pain, plus who is most at risk and when to get ...

Truqap extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer compared to placebo, with a median rPFS of 33.2 months. Truqap was associated with higher rates of ...

The former Top Gear host, 66, shared the news in the latest episode of Clarkson's Farm and said the disease is 'aggressive' but had been discovered early.

Prostate cancer is often called a “silent killer,” and for good reason. You don’t get a big set of warnings, and for a lot of ...

Talazoparib plus enzalutamide met the primary endpoint in TALAPRO-2, lowering radiographic progression or death risk by 37% versus enzalutamide, with median rPFS not reached. Efficacy signals extended ...

In some cases, prostate cancer resists all known therapies and turns extremely deadly. Now, a discovery at Cold Spring Harbor Laboratory (CSHL) points to a potential solution. Researchers led by CSHL ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...